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ReviewMonoclonal antibodies (mAbs) and antibody fragments
represent the most important biopharmaceutical pro-
ducts today. Because full length antibodies are glycosy-
lated, mammalian cells, which allow human-like N-
glycosylation, are currently used for their production.
However, mammalian cells have several drawbacks
when it comes to bioprocessing and scale-up, resulting
in long processing times and elevated costs. By contrast,
antibody fragments, that are not glycosylated but still
exhibit antigen binding properties, can be produced in
microbial organisms, which are easy to manipulate and
cultivate. In this review, we summarize recent advances
in the expression systems, strain engineering, and
production processes for the three main microbials
used in antibody and antibody fragment production,
namely Saccharomyces cerevisiae, Pichia pastoris,
and Escherichia coli.
Introduction
Over the past three decades, the biopharmaceutical mar-
ket has become a significant component of the global
pharmaceutical market accounting for around 40% of its
sales. The use of organisms as biopharmaceutical produc-
tion factories offers several advantages over chemical syn-
thesis. Microorganisms can produce high molecular weight
compounds such as proteins [1] and carry out highly enan-
tio- and regio-selective reactions by their native enzymatic
machinery – these reactions are hard to achieve by chemi-
cal synthesis. The use of microorganisms also enables
repeated implementation of immobilized enzymes or cells
resulting in the reduction of the overall production costs
[2]. Finally, processes employing microorganisms do not0167-7799/     
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Open access under CC BY license.generate organic and inorganic pollutants, such as mercu-
ry and toluene [3].
The biopharmaceutical market originated in the late
1970s with the establishment of recombinant DNA tech-
niques. The industrial interest materialized almost imme-
diately and in 1982 the US Food and Drug Administration
(FDA) approved the commercialization of humulin, the
human insulin analog, recombinantly produced in the
bacterium E. coli [4]. For a while the FDA only allowed
the transformation of bacteria and the expression of small,
non-glycosylated proteins, like insulin, due to concern
about introducing new toxicities such as contaminating
bacterial substances, which raise immunogenic reactions
in patients. However, with the development of selectable
resistance markers, like antibiotic resistance markers, and
the possibility of production in eukaryotic organisms, the
FDA began showing increasing flexibility towards biotech-
nological innovation, leading to a continually increasing
number of approved new biological entities (NBEs). In
2012, the biopharmaceutical market turnover was estimat-
ed at around 100–120 billion US dollars per year [5], with
more than 200 biopharmaceutical proteins already on the
market [6], and is expected to reach 170 billion US dollars
in 2014. This exceptionally high market turnover is largely
derived from the marketing of mAbs and antibody frag-
ments that currently represent the fastest growing class of
approved biopharmaceutical products. In fact, production
of full length mAbs (Figure 1) is the most important
biopharmaceutical venture to date, with several therapeu-
tic products reaching blockbuster status (e.g., Avastin,
Herceptin, Remicade, Rituxan, Humira, and Erbitux).
More recently, interest has grown in the production of
antibody fragments that can be used not only in therapeu-
tic applications but also in immunodetection, purification,
and bioseparation applications [7]. Antibody fragments
still exhibit antigen binding properties and can be pro-
duced in microbials, which are easy to manipulate and
cultivate. In this review, we summarize recent advances in
the expression system, strain engineering, and production
process for the three main microbials for antibody frag-
ment production, namely S. cerevisiae, P. pastoris, and
E. coli, and highlight ongoing research that may allow full
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Figure 1. Schematic view of a full length antibody (the antigen binding sites are
highlighted in yellow).
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mAbs and antibody fragments: an overview
A full length mAb consists of the constant Fc (crystallizable
fragment) domain and an antigen binding domain, com-
prising the Fv (variable fragment) and the Fab region
(antibody binding fragment; Figure 1). Native full length
mAbs are glycosylated during their synthesis. Although
the glycosylated Fc domain does not directly interact with
antigens, it stabilizes the antibody and is important for
antibody-dependent, cell-mediated cytotoxicity. Moreover,
glycosylation strongly impacts the clearance rate of the
recombinant mAb from the body, and incompatible glyco-
forms can cause severe immunogenic effects in patients.
Thus, much current work is focused on optimizing and
controlling glycosylation events in mammalian cells [8],
which at this time are the most often used cell type for the
production of mAbs (Box 1).
Nevertheless, a full length antibody with a glycosylated
Fc domain is not necessary for antigen recognition. In fact,
both the Fv and the Fab region alone (Figure 1) exhibit
antigen binding properties. Furthermore, antibody frag-
ments show increased tissue penetration and a lower
retention time in non-target tissues compared to mAbs
[9]. Although the lack of the stabilizing Fc domain causes
reduced stability [10], the absence of glycosylation on both
the Fv and the Fab regions allows their production to be
less complex and enables easier engineering and cultiva-
tion of microbial host organisms such as bacteria and
yeasts.
Microbial expression hosts for mAbs and antibody
fragments
The yeast S. cerevisiae
S. cerevisiae was the first yeast employed in the production
of recombinant proteins, and several biopharmaceuticals
produced in this yeast have since been successfully mar-
keted [11]. There are several intrinsic characteristics, like
the stability of the expression system and the ease of
cultivation, as well as advances in host engineering, thatmake S. cerevisiae an attractive host for the production of
mAbs and antibody fragments. In fact, the production of
Llama heavy chain antibody fragments (Hvv) in S. cerevi-
siae already represents a well-established industrial pro-
cess, ensuring production titers up to hundreds of mg/l [12].
Expression system. S. cerevisiae is easy to transform
either chemically or by electroporation. There are three
main types of shuttle vectors in use: (i) yeast episomal
plasmids (Yep), which contain the 2 m origin of replication,
allowing gene expression without genomic integration at
high copy numbers; (ii) yeast centromeric plasmids (Ycp),
which contain an autonomously replicating sequence and
replicate with single or very low gene copy number; and (iii)
yeast integrative plasmids (Yip), which lack the yeast
origin of replication and are integrated into the host ge-
nome [13]. Although genomic integration of the target gene
leads to a reduced expression level, it is highly desirable in
terms of process quality and stability [14]. To overcome the
disadvantage of low expression, targeted integration of the
heterologous gene at the highly transcribed ribosomal
DNA locus was developed recently [15]. In addition, com-
monly used promoters derived from the native glycolytic
pathway, such as the promoters for glyceraldehyde-3-
phosphate dehydrogenase (GAP), alcohol dehydrogenase1
(ADH1), phosphoglycerate kinase (PGK), and phosphoglyc-
erate kinase (PGK1), allow high transcription levels [16].
Finally, new cloning strategies introduced recently allow
the concomitant expression of two or more genes located on
specially designed self-replicating plasmids [17], which
also addresses the issue of low expression levels of heter-
ologous genes caused by genomic integration.
Strain engineering. Despite continuing advances in ge-
netic manipulation, efficient production of mAbs and anti-
body fragments in S. cerevisiae can still be impaired by
endoplasmic reticulum (ER) misfolding and inefficient
trafficking. Although Hvv can be produced successfully
in sufficient amounts [12], the expression of the signifi-
cantly smaller single chain Fv (scFv) region (Figure 1)
leads to intracellular accumulation of misfolded proteins
in the ER or in vacuolar-like organelles. A possible expla-
nation for this is the higher hydrophobicity of the variable
light and heavy chains of scFv compared to Hvv [18].
However, additional overexpression of chaperones and
foldases can correct protein folding and allow subsequent
scFv secretion [19].
Several strategies have been developed to increase
the overall secretory capacity and productivity of
S. cerevisiae. These approaches include engineering in-
tracellular protein trafficking by over-expression of solu-
ble N-ethylmaleimide-sensitive factor (NFS) attachment
protein receptor proteins (SNAREs) [20], reduction of
proteolytic degradation by multiple protease gene dele-
tions [21], and engineering of the heat shock response
(HSR) pathway by overexpressing the heat shock tran-
scription factor (Hsf) [22]. Although these engineered
strains have not yet been used for the production of
mAbs and antibody fragments, they demonstrate the
ongoing, intensive strain engineering work that is being
done with S. cerevisiae.55
Box 1. Production of mAbs in mammalian cells: advantages
and drawbacks
Mammalian cells are used most often for production of mAbs due to
their ability to perform post-translational modifications (PTM),
especially human-like N-glycosylation. Their use simplifies subse-
quent medical applications by eliminating the risk of an immuno-
genic response in patients due to incompatible N-glycans on the
protein. Chinese Hamster Ovary (CHO) cell lines are used most
frequently to generate full length mAbs with human-like Fc N-
glycosylation and production titers of around 10 g/l [8]. However,
the use of mammalian cells for heterologous protein expression
holds several drawbacks such as low product yield and growth rate,
risk of viral contamination, and requirement for serum. Despite the
introduction of serum-free (SF) chemically defined media (CDM)
encountering regulatory requirements [56], the addition of chemi-
cally undefined hydrolysates is still necessary to support cell
growth. This, however, highly contradicts QbD guidelines demand-
ing defined growth media [57]. Furthermore, the current standard
production process is cumbersome and time-consuming. Cell
transfection leads to high clone heterogeneity, necessitating
repeated screening procedures at increasing drug concentrations
for the isolation of a positive, highly productive clone [8]. Clone
evaluation and culture condition optimization is then performed in
shake flasks and lab-scale bioreactors before production processes
can be set up. However, scale-up is also very challenging. The
catabolism of the main carbon sources, glucose and glutamine,
leads to formation of the inhibiting metabolites lactate and
ammonium, respectively; hence batch and fed-batch operation
modes, both representing closed cultivation systems, are only
possible for a restricted timeframe. Because the metabolism of
mammalian cells is highly sensitive and responsive to changing
culture conditions, bioprocesses are hard to model – in fact only
unstructured models are possible – and to control, which again
contradicts QbD guidelines [57]. Consequently, chemostat cultiva-
tions, which describe open cultivation systems where substrate is
constantly fed and cultivation broth is continuously removed, are
generally employed to avoid metabolite inhibition. To avoid a
critical wash out of mammalian cells, perfusion systems that
provide cell retention by employing membranes are mainly used.
However, operating a continuous culture with a perfusion system
requires more devices and control systems than a batch or fed-batch
system and also bears the elevated risk of contamination. Another
drawback associated with scaling-up mammalian cell cultures is
their sensitivity to shear stress, creating further challenges to
efficient aeration in large vessels. Thus, although mammalian cells
can produce mAbs with compatible PTMs, several drawbacks in
bioprocessing are yet to be overcome.
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S. cerevisiae is generally done in glucose-limited fed-batch
cultivations [12]. Yeast shows a mixed oxidative/fermenta-
tive metabolism, which can result in the undesired pro-
duction of toxic metabolites. Fermentative mode shift is
triggered by oxygen depletion or by elevated carbon source
concentration. Limiting glucose is therefore a valid strate-
gy for preventing fermentation during cultivation process-
es with this yeast. Recently, a fully aerobically engineered
strain, in which glucose uptake was reduced, was devel-
oped, allowing a full aerobic respiration even at elevated
glucose concentrations [23].
As this discussion indicates, there are ongoing efforts to
optimize the yeast S. cerevisiae for the production of mAbs
and antibody fragments. Because antibody fragments are
not glycosylated, they can be produced successfully in this
yeast and are not affected by hypermannosylation, which
characterizes S. cerevisiae [24]. Furthermore, current
studies are investigating the possibility of humanizing
the glycosylation machinery in S. cerevisiae [25], in an56attempt to engineer this yeast for the production of full
length mAbs.
The yeast P. pastoris
As an alternative to S. cerevisiae, the methylotrophic yeast
P. pastoris, which is closely related to S. cerevisiae, can be
used for the production of mAbs and antibody fragments as
it also holds a generally recognized as safe (GRAS) status
[26].
Expression system. Similar to the process in S. cerevisiae,
the target gene is integrated into the genome of P. pastoris
to guarantee reproducibility and stability of the expression
system. However, a major obstacle in P. pastoris is the
substantial degree of non-homologous recombination. One
solution to this challenge is the use of a recently developed
P. pastoris strain with an inactivated non-homologous end
joining pathway [27].
P. pastoris can use methanol as a sole carbon source, as
it is a crucial part of its metabolism (e.g., [28]). However,
instead of the traditional hard-to-control alcohol oxidase
promoter system typically used for P. pastoris, alternative
adjustable promoters are currently under investigation
[29]. Furthermore, the generation of artificial and semi-
artificial, tunable promoter variants are the subject of
recent synthetic biology approaches [30].
Strain engineering. The genome sequences of the wild
type strains NRRL Y-1603 (identical to DSMZ 70382 or
CBS704) [7], NRRL Y-11430 (identical to ATCC 7673 or
CBS7435), and GS115 are available online [31,32] and a
genome-scale metabolic model of P. pastoris was published
recently [33], allowing straight-forward strain engineer-
ing approaches. For example, co-overexpression of helper
proteins, such as the protein disulfide isomerase or the
transcription factor of the unfolded protein response Hac1
[34], as well as inactivation of endogenous proteases (e.g.,
[35]) enhances the production and secretion of recombi-
nant proteins. Engineering the protein trafficking path-
way represents another successful approach to improve
secretion [36]. In addition, intensive glycoengineering
work is ongoing to humanize the glycosylation events in
P. pastoris and allow production of full length mAbs in this
yeast (Box 2).
Production process. In contrast to S. cerevisiae, P. pas-
toris prefers respiratory over fermentative growth, allow-
ing cultivations to very high cell densities, for example,
160 g/l cell dry weight [37], on inexpensive, defined media
without the risk of accumulating ethanol. The very well-
studied production processes in P. pastoris are most com-
monly performed as fed-batch processes. The possibility of
performing mixed-feed fed-batch cultivations, where two
substrates are concomitantly fed facilitating biomass
growth due to higher biomass yields on the second sub-
strate and leading to lower oxygen consumption and lower
heat production, is a significant advantage of yeasts over
mammalian cells and has already been applied successful-
ly for the production of scFvs with P. pastoris [38]. In
addition, a recent study presented a dynamic approach
for determining strain-specific parameters in simple batch
Box 2. Glycoengineering of Pichia pastoris allows mAb
production
P. pastoris can be used for the production of both antibody
fragments and mAbs (e.g., [58]). For mAbs, the correct human-type
glycosylation is not only essential for proper folding and biological
activity, but also for targeting and stability in circulation. P. pastoris
lacks the Golgi-resident a-1,3-mannosyltransferase, but harbors four
additional b-mannosyltransferases instead [59,60]. The absence of
terminal a-1,3-mannoses on P. pastoris-derived glycoproteins is of
importance because this glycan structure causes high antigenicity in
humans [61]. Thus, the humanization of the N-glycosylation path-
way in P. pastoris has been an important goal. The Outer CHain
elongation 1 gene (OCH1) coding for an a-1,6-mannosyltransferase
was knocked out [62], and an a-1,2-mannosidase, b-N-acetylgluco-
saminyltransferase I (GnTI) and an UDP-GlcNAc transporter were
introduced [63]. The Kluyveromyces lactis UDP-GlcNAc transporter,
mouse a-1,2-mannosidase IA, Drosophila melanogaster mannosi-
dase II, human GnTI, and rat GnTII were introduced into an och1
knockout strain, resulting in the homogeneous formation of the
complex human GlcNAc2Man3GlcNAc2 glycan [64]. In other studies,
OCH1 was inactivated via a knock-in strategy [65], an ER-targeted
HEDL (His-Asp-Glu-Leu; C-terminal tetrapeptide involved in the
lumen sorting of soluble proteins)-tagged a-1,2-mannosidase from
Trichoderma reesei was introduced, and a chimeric human GnTI
was fused to the N-terminal part of Saccharomyces cerevisiae Kre2
for Golgi localization [66]. A further approach included the
construction of a strain expressing mouse mannosidase IA, the K.
lactis UDP-GlcNAc transporter, human GnTI, and rat GnTII, in which
the ALG3 gene, encoding an a-1,3-mannosyltransferase of the ER
lumen, was knocked out [67], leading to the formation of
GlcNAc2Man3GlcNAc2. Additional coexpression of a fusion protein
consisting of the S. cerevisiae Mnn2 Golgi localization domain and
the activities of Schizosaccharomyces pombe UDP-Gal 4-epimerase
and human b-1,4-galactosyl transferase allowed the production of
Gal2GlcNAc2Man3GlcNAc2 glycans. An alternative protocol allowed
production of Gal2GlcNAc2Man3GlcNAc2 N-glycans using the
GlycoSwitch vector technology [68], where specially designed
vectors are used to replace genes of the native glycosylation
pathway. Further humanization was achieved by additional biosynth-
esis of cytidine monophosphate-linked Sia, its transport and the
transfer of Sia onto the N-glycans of nascent polypeptides, leading to
complex human Sia2Gal2GlcNAc2Man3GlcNAc2 glycans [69].
Additional glycoengineering studies included the elimination of
a-1,2-mannosidase-resistant high Man glycans [70] and overexpres-
sion of Leishmania major STT3D to increase N-glycan site occupancy
[71]. These steps make it possible to use glycoengineered P. pastoris
strains for the production of full length mAbs (e.g., [72]).
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mixed-feed strategies for this yeast [39].
In conclusion, P. pastoris is a well-established host
system for the production of antibody fragments. In fact,
two recombinant therapeutic antibody fragments are al-
ready on the market: Nanobody ALX0061, which is a
recombinant anti-IL6 receptor single domain antibody
fragment used for rheumatoid arthritis treatment, and
Nanobody1 ALX00171, a recombinant anti-RSV single
domain antibody fragment used for respiratory syncytial
virus (RSV) infection treatment. Given recent and ongoing
advances in glycoengineering, P. pastoris is of increasing
interest for the production of glycosylated full length mAbs
(Box 2).
The bacterium E. coli
Due to rapid growth on inexpensive substrates, the ability
to reach high cell densities, well-understood genetics, and
easy genetic manipulation, prokaryotic expression systems
are widely used for the production of recombinant proteins.The gram-negative bacterium E. coli was the first microbi-
al organism employed for the production of recombinant
biopharmaceuticals and still accounts for nearly 40% of all
the marketed biopharmaceutical compounds produced to-
day. After the approval of humulin in 1982, several differ-
ent therapeutic proteins, such as antibody fragments [e.g.,
the antitumor necrosis factor (TNF)-a Fab], have been
successfully produced in this prokaryotic organism [11].
Expression system. Recombinant protein expression in
bacterial hosts is generally driven by self-replicating multi-
copy plasmids carrying a strong promoter, like the bacte-
riophage T7, the E. coli lactose operon (lac) or the synthetic
tryptophan operon (trp) promoter, and a ribosome binding
site allowing high gene dosages [40]. Although greater
volumetric productivity can be reached by implementing
self-replicating multicopy plasmids, these cause a severe
metabolic burden for E. coli, including cell growth inhibi-
tion and cell death. Thus, new plasmid-free expression
systems, based on site-directed chromosomal integration
of the heterologous DNA, have been developed [41]. In
order to eliminate the metabolic burden associated with
the selection marker, a novel marker-free plasmid selec-
tion system using a genomically modified E. coli strain was
also engineered [42].
Strain engineering. Although cytoplasmic production in
E. coli allows high intracellular product yields, it is often
associated with inclusion body formation (e.g., [43]). This
E. coli characteristic phenomenon arises from unbalanced
expression of folding helper elements and the fact that
disulfide bridges cannot be formed correctly in the reduc-
tive environment of the cytoplasm. This problem can be
overcome by the co-expression of chaperones [44] or by the
transport of the target protein to the periplasmic space by
fusion to a leader peptide at the N terminus [45]. Secretion
into the periplasm has already been successfully per-
formed for antibody fragments [46]. However, if efficient
refolding is possible, recombinant protein production in
inclusion bodies also describes a valuable production strat-
egy, as already described for Fc-fusion proteins [47].
Production process. Due to the intrinsic high growth rate
of E. coli, high cell density cultures are currently used for
the production of antibody fragments [48]. Production
processes with E. coli are commonly conducted in stirred
tank reactors (STR) as limited glucose fed-batch processes
because glucose excess induces overflow metabolism and
causes the production of the inhibiting metabolite acetate.
As an alternative to a carbon source-limited feeding strat-
egy, different metabolic engineering approaches have been
designed to prevent or at least reduce acetate formation.
These approaches include manipulating the native acetate
formation pathway [49] and engineering the endogenous
glucose uptake system [50]. Another recent advance is to
improve the bioprocess via the identification and charac-
terization of key strain-specific physiological parameters
instead of excessive strain engineering. The knowledge of
the strain characteristic parameters specific substrate
uptake rate (qs) and maximum specific substrate uptake
rate (qs max), for example, allows the design of tailored57
Table 1. Recent advances in the production of full length mAbs and antibody fragments with different host organisms
Production milestone Recent advances
Mammalian cells Refs Yeasts Refs Escherichia coli Refs
Stable and efficient
expression system
Site-specific homologous
recombination
Vector engineering and marker
attenuation
Expression of anti-apoptotic
genes
[73]
[74,75]
[76]
Targeted gene integration
Concomitant expression
of several genes
Co-expression of chaperones
Reduction of proteolysis
Over-expression of Hsf
[15]
[17]
[34]
[21,35]
[22]
Plasmid-free expression system
Marker-free selection system
Co-expression of chaperones
[41]
[42]
[44]
Clone selection Robotics and fluorescence-
activated cell sorting
[75] Targeted gene integration
Optimization of codons, gene
copy number, and promoters
[15]
[77]
Not an issue
Disulfide bridges Intrinsic feature of the ER Intrinsic feature of the ER Transport to the periplasm [46]
Product secretion Intrinsic feature Over-expression of SNAREs
Mutation studies on MFa1
System biological analysis
[20]
[78]
[77]
Transport to the periplasm [46]
Chemically defined
medium (CFD)
Serum-free CFD [56] Already applied Already applied
Efficient bioprocess Concentrated fed-batch strategy [79] Fully aerobic strain
Dynamic processes
[23]
[80]
Manipulating the native
acetate formation pathway
Engineering the glucose
uptake system
[49]
[50]
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tools, which are virtual sensors processing different signals
measured online that give real-time information on a non-
measurable process parameter, are powerful tools for that
purpose [51]. Besides, strain-specific physiological param-
eters can easily be determined by applying dynamic changes
of process parameters during cultivation [52]. The availabil-
ity of detailed physiological data enables design that follows
the Quality by Design (QbD) guidelines [53].
In summary, antibody fragments, which are not glyco-
sylated, can be produced in E. coli and the required tools
are already in place (e.g., [11]). Remarkably, successful
production of full length mAbs in E. coli was achieved
recently, although the mAbs were not glycosylated [47].
The identification of the N-glycosylation pathway in Cam-
pylobacter jejuni and the possibility of introducing it into E.
coli [54] may pave the way for the production of the
glycosylated Fc domain [55] and the successful expression
of full length mAbs in E. coli. For this reason, pharmaceu-
tical companies are now investing effort and capital in re-
introducing E. coli to their production facilities.
Concluding remarks and future perspectives
Full length mAbs as well as antibody fragments represent
the most important and valuable class of biopharmaceu-
ticals today. Due to the requirement for surface glycosyla-
tion, mAbs are still predominantly produced in
mammalian cells, which possess several drawbacks relat-
ing to bioprocessing and scale-up. By contrast, antibody
fragments, which are not glycosylated but retain antigen
binding properties, can also be produced in microbial
organisms. Recent advances in the production of full length
mAbs and antibody fragments with both mammalian cells
and microbials are summarized in Table 1.
As shown in Table 1, current efforts are directed to-
wards optimizing the production of mAbs and antibody
fragments in microbial organisms, because they outpace
mammalian cells in several aspects, such as the ease of
genetic manipulation, greater productivity, and high cell
density cultivation processes on inexpensive and defined58substrates. Although mAbs are still most frequently pro-
duced in mammalian cells, ongoing glycoengineering stud-
ies with yeasts (Box 2) and E. coli [54,55] are paving the
way for the successful production of glycosylated full length
mAbs in microbial host organisms.
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